From ₹4 crore to free: Hyderabad doctor brings hope to seven children with rare disorder

HYDERABAD: Seven children diagnosed with Allan-Herndon-Dudley syndrome (AHDS), a rare genetic disorder, will receive the medicine Tiratricol free of cost for one year following efforts by doctors, activists and international organisations.
The development comes after a prolonged effort to secure the medicine at an affordable price. Tiratricol was not available in India, while its reported annual cost through Egetis Therapeutics was around ₹4 crore per child.
Pediatrician Dr Sivaranjini, who shared the account, said a mother had approached her seeking help for her child diagnosed with the condition, also known as MCT8 deficiency.
“I tried to find a solution as if it were my own child. I couldn’t rest otherwise,” she said.
Same medicine. ₹4 crore a year vs ₹2.5 lakh a year. 💔
A helpless mom came to me with her child, who has Allan-Herndon-Dudley syndrome (MCT8 deficiency). It was very painful to see them so helpless. I tried to find a solution as if it were my own child. I couldn’t rest otherwise.
Tiratricol wasn’t available in India. Dr Santosh and I wrote to doctors. Dr Praveen and others directed us to the Erasmus team, who did the trials for Tiratricol. After many emails, they suggested Egetis Therapeutics might be able to support the child. I teared up. But our happiness was short-lived: Egetis said it could not give us the medicine.
I wrote to many journalists. I posted on Instagram and tagged the PM. Someone told me Tiratricol was available in Germany. The mother bought it, paying ₹12 lakh for just one month. That’s impossible to keep up for life, for this child or for the five other children with the same condition under Dr Praveen’s care at CMC Vellore.
Finally, Toufiq, a senior journalist, wrote about it, and it reached the Pharmaceutical Accountability Foundation in the Netherlands. They said Tiratricol can be made available at ₹2.5 lakh per child per year, against ₹4 crore per child per year by Egetis!
I raised funds, and the Pharmaceutical Accountability Foundation raised funds. Now 7 children are getting the medicine free of cost for one whole year. (The 7th child was added after my Instagram post.) 🙏
Thank you to Access to Medicines India and Organization for Rare Diseases India for their important role, and to geneticist Dr Kishore, who helped us reach the diagnosis.
India can compound the Active Pharmaceutical Ingredient here and make it available to every child with this condition at a reasonable cost.
👉 Please tag @narendramodi @JPNadda @MoHFW_INDIA
People of India, you can make it happen! Please share. 🙏All the paediatricians, endocrinologists, paediatric endocrinologists, and paediatric neurologists, if you are currently caring for a child with confirmed or suspected MCT8 deficiency, please share the details below. Our team may contact you for further clinical information and coordination regarding diagnosis, treatment and access to tiratricol.
Please do not upload or share unnecessary patient-identifying information at this stage.
https://t.co/k98Hxikwhc
#AllanHerndonDudley #MCT8Deficiency #Tiratricol #Triac #Emcitate #RareDiseases #RareDiseaseIndia #AccessToMedicines #PharmaHijack #ChildHealth
— Dr.Sivaranjini (@dr_sivaranjani) November 4, 2026
Doctors approached international experts to secure access to Tiratricol
Dr Sivaranjini wrote to several doctors seeking access to the medicine. Dr Praveen and others directed them to the Erasmus team, which had conducted clinical trials involving Tiratricol.
Following several email exchanges, the team suggested approaching Egetis Therapeutics for possible assistance. However, the company said it could not provide the medicine to the child.
Dr Sivaranjini then contacted several journalists and raised the issue on Instagram, tagging the Prime Minister.
The child’s mother later learnt that Tiratricol was available in Germany. She purchased the medicine at a cost of ₹12 lakh for a month’s supply.
Dr Sivaranjini said this was financially unsustainable, particularly for lifelong treatment. She also highlighted the needs of five other children with the same condition under Dr Praveen’s care at Christian Medical College (CMC), Vellore.
Netherlands foundation helps secure medicine at lower cost
The issue gained wider attention after senior journalist Toufiq published a report. It subsequently reached the Pharmaceutical Accountability Foundation in the Netherlands.
According to Dr Sivaranjini, the foundation said Tiratricol could be made available at ₹2.5 lakh per child annually. This compares with the ₹4 crore annual cost quoted in relation to Egetis Therapeutics.
Dr Sivaranjini and the foundation raised funds to support the treatment. As a result, seven children will receive the medicine free for one year. The seventh child was included after her Instagram post.
She thanked Access to Medicines India and the Organisation for Rare Diseases India for their role in the effort. She also acknowledged geneticist Dr Kishore for helping the family reach the diagnosis.
Dr Sivaranjini said India could compound the active pharmaceutical ingredient (API) domestically and make the medicine available to every child with the condition at an affordable cost.
